Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04388124 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Endothelin-1 Receptor Blockade in Resistant Hypertension

Study acronym: ENDOTHELIN-2
StatusRecruiting
PhasePhase 2
Started2021-10-20
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 17, 2026 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-02-12
Not Yet Recruiting→Recruiting Study Identification, Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2022-11→2026-08
Completion date2022-11→2026-08
Start dateestimated 2020-09→confirmed 2021-10-20
Study title-52 characters
VASCULAR AND RENAL IMPACT OF ENDOTHELINEndothelin-1 RECEPTORReceptor BLOCKADEBlockade INin PATIENTSResistant WITH RESISTANT ARTERIAL HYPERTENSIONHypertension
2020-05-13
Original filing
The management of patients with resistant arterial hypertension, who are characterized by a very high cardiovascular risk, remains a major therapeutic issue. The use of endothelin-1 (ET-1) receptor antagonists, in addition to lowering blood pressure, may also improve endothelial function in these patients. The objective of this study is to assess the vascular impact of an ET-1 receptor antagonist on vascular function and systemic and central hemodynamics in patients with resistant arterial hypertension and ensure their good renal tolerance.
Trial Details
NCT Number NCT04388124
Lead Sponsor University Hospital, Rouen
Conditions Resistant Hypertension
Enrollment 24 participants
Start Date 2021-10-20
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-17